image credit- shutterstock
Reprocell Inc. has entered into a basic agreement with Toho Holdings toward a partnership concerning the domestic distribution and related activities of the regenerative medical product “Stemchymal®”, for which the company has submitted an application for manufacturing and marketing approval in Japan.
The company has submitted an application for manufacturing and marketing approval in Japan for Stemchymal, with the indication of suppressing the progression of ataxia in patients with spinocerebellar ataxia (SCA3 and SCA6).
Under the basic agreement, the company and Toho will discuss and consider the establishment of a supply system for medical institutions nationwide utilising the pharmaceutical distribution network of the Toho Holdings Group, as well as a distribution system tailored to the characteristics of regenerative medical products, with the aim of enabling a smooth market launch and stable supply of Stemchymal following manufacturing and marketing approval.
In parallel with its efforts to obtain manufacturing and marketing approval for Stemchymal, the company is working to establish a system for the stable supply of the product to medical institutions nationwide following approval and will make every effort to deliver a new treatment option to patients with spinocerebellar ataxia as soon as possible.
